Attenuated reovirus
AssigneesUniversity Technologies International Inc., UTI Limited Partnership
InventorsManbok Kim, Randal N. Johnston
Life of this patent
Estimating the term…
Abstract
Compositions and methods are provided that relate to an attenuated reovirus exhibiting oncolytic activity toward cancer cells while displaying reduced lytic activity toward non-malignant cells. Exemplified is an attenuated human reovirus derived from persistently infected fibrosarcoma cells that lacks wild-type reovirus S1 and S4 genes and consequently lacks a detectable reoviral outer capsid σ1 protein and expresses a mutated reoviral outer capsid σ3 protein.
Claims26
An attenuated reovirus, comprising a reovirus genome that lacks a wild-type reovirus S1 gene.
6-10. (canceled)
An attenuated reovirus, comprising a reovirus genome that lacks or is incapable of encoding a reovirus S1 gene which is capable of encoding a reovirus σ1 capsid protein having an amino acid sequence selected from the group consisting of (i) an amino acid sequence that is greater than 10% identical to the sequence set forth in SEQ ID NO:2, 4, 6 or 8, (ii) an amino acid sequence that is greater than 20% identical to the sequence set forth in SEQ ID NO:
- 2, 4, 6 or 8, (iii) an amino acid sequence that is greater than 40% identical to the sequence set forth in SEQ ID NO:
- 2, 4, 6 or 8, (iv) an amino acid sequence that is greater than 50% identical to the sequence set forth in SEQ ID NO:
- 2, 4, 6 or 8, (v) an amino acid sequence that is greater than 70% identical to the sequence set forth in SEQ ID NO:
- 2, 4, 6 or 8, (vi) an amino acid sequence that is greater than 90% identical to the sequence set forth in SEQ ID NO:
- 2, 4, 6 or 8, and (vii) an amino acid sequence that is greater than 95% identical to the sequence set forth in SEQ ID NO:
- 2, 4, 6 or 8.
(canceled)
20-23. (canceled)
A method of treating an activated oncogene-associated malignant condition, comprising:
- (a) administering an effective amount of an attenuated reo virus to a subject having an activated oncogene-associated malignant condition, under conditions and for a time sufficient for the attenuated reovirus to mediate an oncolytic effect;
- or (b) contacting one or a plurality of malignant cells from a subject having an activated oncogene-associated malignant condition with an effective amount of an attenuated reovirus, under conditions and for a time sufficient for the attenuated reovirus to mediate an oncolytic effect.
26-27. (canceled)
Dependencies are inferred from the claim text.